Protocol Ledger

NCT04417257 · Phase II/III · TERMINATED

Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

Interventional Phase II/III clinical trial protocol NCT04417257 sponsored by Laurent Pharmaceuticals in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-18 Enrollment: 351 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04417257
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)351 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04417257
Protocol FieldVerified Registry Value
NCT IdentifierNCT04417257
Consolidated Lead SponsorLaurent Pharmaceuticals
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment351 participants (ACTUAL)
Registered Start Date2020-08-18
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI